bluebird bio has received $9.3m Strategic Partnership Award from California Institute for Regenerative Medicine (CIRM) to support phase 1/2 studies of LentiGlobin to treat beta-thalassemia. bluebird bio chief medical officer David ...
Tags: bluebird bio, LentiGlobin, CIRM